

Alex G Ortega-Loayza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/13876/publications.pdf>

Version: 2024-02-01

113
papers

1,960
citations

304743

22
h-index

315739

38
g-index

115
all docs

115
docs citations

115
times ranked

1747
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology of pyoderma gangrenosum (PG): An updated review. Journal of the American Academy of Dermatology, 2015, 73, 691-698.	1.2	212
2	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. Journal of Investigative Dermatology, 2018, 138, 2315-2321.	0.7	94
3	Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Frontiers in Immunology, 2019, 10, 1059.	4.8	92
4	Insights Into the Pathogenesis of Sweet's Syndrome. Frontiers in Immunology, 2019, 10, 414.	4.8	88
5	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis ABCD-10. JAMA Dermatology, 2019, 155, 448.	4.1	69
6	Diversity in dermatology: Roadmap for improvement. Journal of the American Academy of Dermatology, 2018, 79, 337-341.	1.2	65
7	Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. American Journal of Clinical Dermatology, 2022, 23, 615-634.	6.7	63
8	Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. Journal of the American Academy of Dermatology, 2018, 78, 1195-1204.e1.	1.2	62
9	Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. British Journal of Dermatology, 2017, 177, 72-83.	1.5	43
10	Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris. JAMA Dermatology, 2020, 156, 668.	4.1	41
11	Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. Journal of Investigative Dermatology, 2021, 141, 59-63.	0.7	41
12	Endemic Pemphigus Vulgaris. Archives of Dermatology, 2007, 143, 895.	1.4	37
13	Clinical Features of Neutrophilic Dermatitis Variants Resembling Necrotizing Fasciitis. JAMA Dermatology, 2019, 155, 79.	4.1	37
14	Cutaneous acanthamebias infection in immunocompetent and immunocompromised patients. International Journal of Dermatology, 2009, 48, 1324-1329.	1.0	36
15	Extracutaneous involvement of pyoderma gangrenosum. Archives of Dermatological Research, 2019, 311, 425-434.	1.9	35
16	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology, 2020, 82, 1553-1567.	1.2	35
17	Acute generalized exanthematous pustulosis: atypical presentations and outcomes. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 209-214.	2.4	33
18	Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. British Journal of Dermatology, 2016, 174, 77-87.	1.5	32

#	ARTICLE	IF	CITATIONS
19	Antibodies against desmoglein 1 in healthy subjects in endemic and nonendemic areas of pemphigus foliaceus (fogo selvagem) in Peru. <i>International Journal of Dermatology</i> , 2006, 45, 538-542.	1.0	31
20	Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. <i>JAMA Dermatology</i> , 2022, 158, 176.	4.1	31
21	Biologic and small-molecule medications in the management of pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2019, 30, 264-276.	2.2	29
22	Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2018, 178, e35-e36.	1.5	25
23	Pyoderma gangrenosum: From historical perspectives to emerging investigations. <i>International Wound Journal</i> , 2020, 17, 1255-1265.	2.9	24
24	Influence of climatic factors on the medical attentions of dermatologic diseases in a hospital of Lima, Peru. <i>Anais Brasileiros De Dermatologia</i> , 2010, 85, 461-468.	1.1	22
25	Characterization of <i>Staphylococcus aureus</i> cutaneous infections in a pediatric dermatology tertiary health care outpatient facility. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 804-811.	1.2	21
26	Microarray Technique, Analysis, and Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1-4.	0.7	21
27	Eosinophilic fasciitis in a female child. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S72-S74.	1.2	20
28	Facial porokeratosis: A series of six patients. <i>Australasian Journal of Dermatology</i> , 2010, 51, 191-194.	0.7	20
29	Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 157-161.	3.1	20
30	Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country. <i>Anais Brasileiros De Dermatologia</i> , 2010, 85, 736-742.	1.1	19
31	A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e89-e90.	1.2	19
32	Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1217-1220.e14.	0.7	18
33	Aspirin Desensitization/Challenge in 3 Patients With Unstable Angina. <i>American Journal of the Medical Sciences</i> , 2010, 340, 418-420.	1.1	17
34	Synergistic induction of IL-23 by TNF α , IL-17A, and EGF in keratinocytes. <i>Cytokine</i> , 2021, 138, 155357.	3.2	17
35	Endemic pemphigus in the peruvian Amazon: epidemiology and risk factors for the development of complications during treatment. <i>Anais Brasileiros De Dermatologia</i> , 2012, 87, 838-845.	1.1	16
36	Cutaneous blastomycosis: a clue to a systemic disease. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 287-289.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1179-1185.	4.1	16
38	Adverse cutaneous reactions to chemotherapeutic drugs. <i>Clinics in Dermatology</i> , 2020, 38, 712-728.	1.6	14
39	Skin diseases in the Peruvian Amazonia. <i>International Journal of Dermatology</i> , 2010, 49, 794-800.	1.0	13
40	Endemic pemphigus foliaceus in the Peruvian Amazon. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 594-600.	1.3	13
41	Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 764-767.e1.	1.2	13
42	Pyoderma gangrenosum: a review with special emphasis on Latin America literature. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 729-743.	1.1	13
43	Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. <i>Annals of Hematology</i> , 2019, 98, 2247-2248.	1.8	13
44	Crusted scabies and multiple dosages of ivermectin. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 584-5.	0.8	13
45	Ocular pyoderma gangrenosum: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 512-518.	1.2	12
46	Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review*. <i>British Journal of Dermatology</i> , 2020, 183, 821-828.	1.5	12
47	Perioperative management of pyoderma gangrenosum. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 369-374.	1.2	12
48	Asociación entre la hidradenitis supurativa y el síndrome metabólico: Revisión sistemática y metaanálisis. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 279-288.	0.4	12
49	Pyoderma gangrenosum study pilot registry: The first step to a better understanding. <i>Wound Repair and Regeneration</i> , 2022, 30, 334-337.	3.0	12
50	Incidental skin malignancies in teledermatology and in-person cohorts in the Veterans Affairs Health System. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 965-966.	1.2	11
51	A systematic review of pyoderma gangrenosum with pulmonary involvement: clinical presentation, diagnosis and management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e295-e297.	2.4	11
52	LPIN2 gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	11
53	Health-related domains of quality of life in pyoderma gangrenosum: A qualitative analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1382-1385.	1.2	11
54	Calciophylaxis: Part I. Diagnosis and pathology. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 973-982.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S64-S68.	0.8	10
56	Pyoderma Gangrenosum: What Do We Know Now?. <i>Current Dermatology Reports</i> , 2018, 7, 147-157.	2.1	10
57	Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2020, 31, 723-726.	2.2	10
58	Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. <i>Clinical Rheumatology</i> , 2021, 40, 3963-3969.	2.2	10
59	Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels. <i>Journal of Investigative Dermatology</i> , 2022, 142, 235-239.e1.	0.7	10
60	Surgical Treatment in Hidradenitis Suppurativa. <i>Journal of Clinical Medicine</i> , 2022, 11, 2311.	2.4	10
61	Update on the characterization of <i>Staphylococcus aureus</i> skin infections in a pediatric dermatology tertiary health care outpatient facility: Antibiotic susceptibility patterns and decreased methicillin resistance. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 440-441.	1.2	9
62	Molecular characterization and antifungal susceptibility of <i>Cryptococcus neoformans</i> strains collected from a single institution in Lima, Peru. <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 88-92.	0.9	9
63	International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. <i>Clinical Rheumatology</i> , 2020, 39, 1839-1850.	2.2	9
64	Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life. <i>Dermatologic Therapy</i> , 2021, 34, e14736.	1.7	9
65	Noninfectious dermatological diseases associated with chronic exposure to mine tailings in a Peruvian district. <i>British Journal of Dermatology</i> , 2008, 159, 169-174.	1.5	8
66	Calciophylaxis with evidence of hypercoagulability successfully treated with unfractionated heparin: a multidisciplinary approach. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 275-278.	1.3	8
67	Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multicentre study. <i>International Wound Journal</i> , 2019, 16, 1440-1444.	2.9	8
68	Modified dose of guselkumab for treatment of pyoderma gangrenosum. <i>JAAD Case Reports</i> , 2022, 21, 38-42.	0.8	8
69	Miliaria-rash after neutropenic fever and induction chemotherapy for acute myelogenous leukemia. <i>Anais Brasileiros De Dermatologia</i> , 2011, 86, 104-106.	1.1	7
70	Wound care dressings for pyoderma gangrenosum. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 458-460.	1.2	7
71	Pyoderma gangrenosum underrepresentation in non-dermatological literature. <i>Diagnosis</i> , 2021, 8, 85-90.	1.9	7
72	Treatment of an ulcerated hemangioma with dehydrated human amnion/chorion membrane allograft. <i>JAAD Case Reports</i> , 2018, 4, 890-892.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Calciphylaxis: Treatment and outlookâ€”CME part II. Journal of the American Academy of Dermatology, 2022, 86, 985-992.	1.2	6
74	Cryptococcus gattii meningoencephalitis in an HIV-negative patient from the Peruvian Andes. Revista Da Sociedade Brasileira De Medicina Tropical, 2010, 43, 469-471.	0.9	5
75	Somatic symptom disorder in dermatology. Clinics in Dermatology, 2017, 35, 246-251.	1.6	5
76	Estudio comparativo del maÃ± morado (Zea mays L.) y simvastatina en la reducciÃ³n de lÃ­pidos sÃ©ricos de pacientes diabÃ©ticos normotensos con dislipidemia. Anales De La Facultad De Medicina, 2012, 73, 113.	0.1	5
77	Historical notes on endemic pemphigus in South America. International Journal of Dermatology, 2012, 51, 477-481.	1.0	4
78	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	2.1	4
79	Amlodipine-induced subacute cutaneous lupus. North American Journal of Medical Sciences, 2013, 5, 246.	1.7	4
80	Management of Classic Ulcerative Pyoderma Gangrenosum. , 2020, 106, 119-123;E2;E3.		4
81	Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. Journal of the American Academy of Dermatology, 2022, 87, 1130-1133.	1.2	4
82	Pyoderma Gangrenosum of the Scalp: A Rare Clinical Variant. Wounds, 2018, 30, E16-E20.	0.5	4
83	Cutaneous Blastomycosis. New England Journal of Medicine, 2013, 368, e13.	27.0	3
84	191 Secukinumab treatment of individuals with psoriasis infected with hepatitis B and/or hepatitis C virus. Journal of Investigative Dermatology, 2017, 137, S32.	0.7	3
85	Carcinoma Erysipeloides From Metastatic Cutaneous Squamous Cell Carcinoma Initially Mistaken for Intralymphatic Histiocytosis. American Journal of Dermatopathology, 2019, 41, 522-525.	0.6	3
86	The utility and challenges of histopathologic evaluation in the diagnosis of nonmalignant skin ulcers. Wound Repair and Regeneration, 2020, 28, 219-223.	3.0	3
87	Aortic Endograft and Epithelioid Sarcoma: A Random Association or Causality?. Journal of Drugs in Dermatology, 2016, 15, 897-9.	0.8	3
88	Multivessel Acute Myocardial Infarction: Case Report and Review of the Literature. American Journal of the Medical Sciences, 2008, 335, 375-378.	1.1	2
89	Reply to: â€œWound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet needâ€. Journal of the American Academy of Dermatology, 2018, 79, e89.	1.2	2
90	Oxidative stress in patients with endemic pemphigus foliaceus and healthy subjects with anti-desmoglein 1 antibodies. Anais Brasileiros De Dermatologia, 2018, 93, 212-215.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Atypical Pyoderma Gangrenosum in the Setting of Venous and Arterial Insufficiency. <i>International Journal of Lower Extremity Wounds</i> , 2023, 22, 418-422.	1.1	2
92	Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. <i>Journal of Clinical Medicine</i> , 2022, 11, 670.	2.4	2
93	Necrolytic acral erythema. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 1370-1.	0.8	2
94	Update on calciphylaxis etiopathogenesis, diagnosis, and management. <i>Cutis</i> , 2018, 102, 395-400.	0.3	2
95	Night Blindness in a Patient With Acquired Immunodeficiency Syndrome. <i>American Journal of the Medical Sciences</i> , 2010, 339, 457.	1.1	1
96	Reply to: pyoderma gangrenosum: a clinical conundrum. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e382.	2.4	1
97	Antidesmoglein 1 and 3 antibodies in healthy subjects of a population in the Peruvian high amazon. <i>International Journal of Dermatology</i> , 2018, 57, 344-348.	1.0	1
98	Do I Have Calciphylaxis?. <i>JAMA Dermatology</i> , 2019, 155, 872.	4.1	1
99	Gap of knowledge in diagnosis of pyoderma gangrenosum in clinical specialties education. <i>Diagnosis</i> , 2021, 8, 421-424.	1.9	1
100	Hidden in plain sight: Considerations for an ulcer of the scalp. <i>Head and Neck</i> , 2022, , .	2.0	1
101	An Approach to Skin Lesions in the Returning Traveler. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 81-89.	1.9	0
102	Vulvar edema and weight loss in a pediatric patient. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e193-e194.	1.2	0
103	Scattered targetoid papules and mucosal erosions after vaccination. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e129-e130.	1.2	0
104	252 Dysregulation of the innate immune system in lesional and non-lesional skin of patients with pyoderma gangrenosum. <i>Journal of Investigative Dermatology</i> , 2017, 137, S43.	0.7	0
105	Primary Immunodeficiency, a Possible Cause of Neutrophilic Necrotizing Dermatitisâ€”Reply. <i>JAMA Dermatology</i> , 2019, 155, 864.	4.1	0
106	Sweet syndrome: A glimpse into the pathophysiology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, AB281.	1.2	0
107	A Treatment-Refractory, Perianal Tumor Arising in an Otherwise Healthy Older Adult Woman. <i>JAMA Dermatology</i> , 2020, 156, 453.	4.1	0
108	Simultaneous endemic pemphigus foliaceus and psoriasis vulgaris in Peru â€œ immunogenetic or environmental factors?. <i>Przegląd Dermatologiczny</i> , 2021, 108, 153-159.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Dapsone and Autoimmune Bullous Disorders. , 2015, , 493-499.		0
110	White concretions on the hair shaft. Cutis, 2019, 103, E8-E9.	0.3	0
111	Successful Mastectomy and Chemotherapy in a Patient with Breast Cancer and Active Generalized Pyoderma Gangrenosum. Wounds, 2020, 32, E19-E22.	0.5	0
112	From the Cochrane Library: Systemic treatments for eczema, a network meta-analysis. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
113	From the Cochrane Library: Interventions for Preventing Occupational Irritant Hand Dermatitis. JMIR Dermatology, 2022, 5, e37961.	0.7	0